FI963630A0 - Nya muteiner av IFN-beta - Google Patents

Nya muteiner av IFN-beta

Info

Publication number
FI963630A0
FI963630A0 FI963630A FI963630A FI963630A0 FI 963630 A0 FI963630 A0 FI 963630A0 FI 963630 A FI963630 A FI 963630A FI 963630 A FI963630 A FI 963630A FI 963630 A0 FI963630 A0 FI 963630A0
Authority
FI
Finland
Prior art keywords
ifn
beta
muteins
those
recombinant dna
Prior art date
Application number
FI963630A
Other languages
English (en)
Finnish (fi)
Other versions
FI120356B (sv
FI963630A (sv
Inventor
Susan E Goelz
Richard L Cate
E Pingchang Chow
R Blake Pepinsky
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of FI963630A publication Critical patent/FI963630A/sv
Publication of FI963630A0 publication Critical patent/FI963630A0/sv
Application granted granted Critical
Publication of FI120356B publication Critical patent/FI120356B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Amplifiers (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
FI963630A 1994-03-15 1996-09-13 Nya muteiner av IFN-beta FI120356B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21344894 1994-03-15
US08/213,448 US5545723A (en) 1994-03-15 1994-03-15 Muteins of IFN-β
PCT/US1995/003206 WO1995025170A1 (en) 1994-03-15 1995-03-13 NOVEL MUTEINS OF IFN-$g(b)
US9503206 1995-03-13

Publications (3)

Publication Number Publication Date
FI963630A FI963630A (sv) 1996-09-13
FI963630A0 true FI963630A0 (sv) 1996-09-13
FI120356B FI120356B (sv) 2009-09-30

Family

ID=22795174

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963630A FI120356B (sv) 1994-03-15 1996-09-13 Nya muteiner av IFN-beta

Country Status (12)

Country Link
US (2) US5545723A (sv)
EP (1) EP0750668B1 (sv)
JP (2) JP3822903B2 (sv)
AT (1) ATE414152T1 (sv)
AU (1) AU695208B2 (sv)
CA (1) CA2185352C (sv)
DE (1) DE69535883D1 (sv)
DK (1) DK0750668T3 (sv)
FI (1) FI120356B (sv)
NO (1) NO318989B1 (sv)
NZ (2) NZ329970A (sv)
WO (1) WO1995025170A1 (sv)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948358B2 (en) * 1996-12-24 2011-11-23 Biogen Idec MA Inc. Stable liquid interferon formulations
PT1121156E (pt) 1998-10-16 2006-05-31 Biogen Idec Inc Conjugados de polimeros de interferao-beta-1a e as suas utilizacoes
DE69931507T2 (de) * 1998-10-16 2007-01-11 Biogen Idec Ma Inc., Cambridge Interferon-beta fusionsproteine und deren verwendungen
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) * 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
ATE432288T1 (de) 2001-02-27 2009-06-15 Maxygen Aps Neue interferon-beta-ähnliche moleküle
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
EP1435979A4 (en) * 2001-09-18 2008-01-23 Novartis Vaccines & Diagnostic METHODS OF TREATING MULTIPLE SCLEROSIS
ZA200700168B (en) 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
AU2003263552A1 (en) 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004028472A2 (en) * 2002-09-27 2004-04-08 Biogen Idec Ma Inc. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β
EP1581631A4 (en) * 2002-10-01 2007-09-05 Xencor Inc INTERFERON VARIANTS HAVING IMPROVED PROPERTIES
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
NZ548255A (en) 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1885858A2 (en) * 2005-05-19 2008-02-13 Bayer Schering Pharma Aktiengesellschaft Treatment of disease using an improved regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
EP1891224A1 (en) * 2005-05-19 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Interferon-beta gene therapy using an improved, regulated expression system
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
PT1917276T (pt) * 2005-08-26 2018-06-11 Ares Trading Sa Processo para a preparação de interferão beta glicosilado
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
WO2008134406A1 (en) * 2007-04-25 2008-11-06 The Board Of Trustees Of The Leland Stanford Junior University Ischemia-induced neovascularization is enhanced by hcns-sc transplantation
EP2076533B1 (en) * 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
EP2379711B8 (en) * 2008-12-23 2017-03-22 BOCO Silicon Valley, Inc. Target populations of oligodendrocyte precursor cells and methods of making and using same
WO2019073315A1 (en) 2017-10-09 2019-04-18 Mansour Poorebrahim ANALOGUE PEPTIDE OF INTERFERON-BETA

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR860001471B1 (ko) * 1980-04-03 1986-09-26 비오겐 엔. 브이 인체의 섬유아세포 인터페론(IFN-β)폴리펩티드의 제조방법
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
DE3683910D1 (de) * 1986-09-05 1992-03-26 Cetus Corp Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL92124A (en) * 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain post-phosphorylation that do not occur in nature
WO1993015609A1 (en) * 1992-02-05 1993-08-19 Thomas Jefferson University Interferon gene therapy for the treatment of vascular disorders

Also Published As

Publication number Publication date
JP3822903B2 (ja) 2006-09-20
ATE414152T1 (de) 2008-11-15
WO1995025170A1 (en) 1995-09-21
US5545723A (en) 1996-08-13
NZ283217A (en) 1998-05-27
NO318989B1 (no) 2005-05-30
DK0750668T3 (da) 2009-03-02
FI120356B (sv) 2009-09-30
AU695208B2 (en) 1998-08-06
AU2120295A (en) 1995-10-03
NZ329970A (en) 2000-01-28
MX9604073A (es) 1997-12-31
NO963837D0 (no) 1996-09-13
JP2006199711A (ja) 2006-08-03
DE69535883D1 (de) 2008-12-24
US6127332A (en) 2000-10-03
FI963630A (sv) 1996-09-13
JPH10500563A (ja) 1998-01-20
EP0750668B1 (en) 2008-11-12
EP0750668A1 (en) 1997-01-02
CA2185352C (en) 2005-02-22
NO963837L (no) 1996-11-14
CA2185352A1 (en) 1995-09-21

Similar Documents

Publication Publication Date Title
FI963630A (sv) Nya muteiner av IFN-beta
DK75694A (da) Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren
EP0787802A3 (sv)
SE9004010D0 (sv) Viralt medel
RU95115239A (ru) Аналог эритропоэтина
WO1995025170B1 (en) NOVEL MUTEINS OF IFN-$g(b)
NO931141L (no) Tnf-muteiner
ATE380866T1 (de) Modulatoren des tnf-rezeptor-assoziierten faktors,deren herstellung und verwendungen
ATE131493T1 (de) Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
ATE100717T1 (de) Intralaesionale behandlung von basalzellenkarzinoma mittels rekombinanten humanen alpha-interferons.
Goelz et al. Muteins of IFN-beta
CA2004202A1 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
DE68918399D1 (de) Lymphokine, DNS-Sequenzen, die diese Lymphokine kodieren, und sie enthaltende pharmazeutische Zusammensetzungen.
IT1262545B (it) Sistema di espressione per linee cellulari eucariotiche
Yamaguchi et al. A procedure for the purification of ferritin using Matrex Red A

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: BIOGEN IDEC MA INC.

Free format text: BIOGEN IDEC MA INC.

FG Patent granted

Ref document number: 120356

Country of ref document: FI

MA Patent expired